Chronic migraine treatment: from OnabotulinumtoxinA onwards

References

• Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629–808.
   PubMed Web of Science ®Google Scholar
• Tana C, Tafuri E, Tana M, et al. New insights into the cardiovascular risk of migraine and the role of white matter hyperintensities: is gold all that glitters? J Headache Pain. 2013;1:9.
   Web of Science ®Google Scholar
• Bellei E, Monari E, Bergamini S, et al. Validation of potential candidate biomarkers of drug-induced nephrotoxicity and allodynia in medication-overuse headache. J Headache Pain. 2015;16:559.
   PubMed Web of Science ®Google Scholar
• Diener HC, Limmroth V. Medication overuse headache: a worldwide problem. Lancet Neurol. 2004;3:475–483.
   PubMed Web of Science ®Google Scholar
• Negro A, Martelletti P. Chronic migraine plus medication overuse headache: two entities or not? J Headache Pain. 2011;12:593–601.
   PubMed Web of Science ®Google Scholar
• Loder E. Triptan therapy in migraine. N Engl J Med. 2010;363:63–70.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Martin VT, Smith T, et al. Cardiovascular tolerability and safety of triptans: a review of clinical data. Headache. 2004;44(Suppl 1):S20–S30.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Serrano D, Reed M, et al. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71:559–566.
   PubMed Web of Science ®Google Scholar
• Lionetto L, Negro A, Palmisani S, et al. Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opin Emerg Drugs. 2012;17:393–406.
   PubMed Web of Science ®Google Scholar
• Negro A, Rocchietti-March M, Fiorillo M, et al. Chronic migraine: current concepts and ongoing treatments. Eur Rev Med Pharmacol Sci. 2011;15:1401–1420.
   PubMed Web of Science ®Google Scholar
• Martelletti P, Giamberardino MA, Mitsikostas -D-D. Greater occipital nerve as target for refractory chronic headaches: from corticosteroid block to invasive neurostimulation and back. Expert Rev Neurother. 2016;24:1–2.
   Google Scholar
• Lionetto L, Borro M, Curto M, et al. Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations. Expert Opin Drug Metab Toxicol. 2016;12:399–406 .
   PubMed Web of Science ®Google Scholar
• Innamorati M, Pompili M, Erbuto D, et al. Psychometric properties of the stagnation scale in medication overuse headache patients. J Headache Pain. 2015;16:1052.
   PubMedGoogle Scholar
• Negro A, D’Alonzo L, Martelletti P. Chronic migraine: comorbidities, risk factors, and rehabilitation. Intern Emerg Med. 2010;5(Suppl 1):S13–S19.
   Google Scholar
• Giamberardino MA, Affaitati G, Costantini R. Visceral referred pain. J Musculoske Pain. 2010;18:403–410.
   Web of Science ®Google Scholar
• Giamberardino MA, Affaitati G, Fabrizio A, et al. Myofascial pain syndromes and their evaluation. Best Pract Res Clin Rheumatol. 2011;25:185–198.
   PubMed Web of Science ®Google Scholar
• Giamberardino MA, Affaitati G, Martelletti P, et al. Impact of migraine on fibromyalgia symptoms. J Headache Pain. 2015;17:28.
   PubMed Web of Science ®Google Scholar
• Aurora SK, Dodick DW, Turkel CC, et al. PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793–803.
   PubMed Web of Science ®Google Scholar
• Diener HC, Dodick DW, Aurora SK, et al. PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double- blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804–814.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Turkel CC, DeGryse RE, et al. PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50:921–936.
   PubMed Web of Science ®Google Scholar
• Allergan Inc. BOTOX (onabotulinumtoxinA) full prescribing information. Irvine: Allergan Inc; 2013.
   Google Scholar
• Martelletti P, Katsarava Z, Lampl C, et al. Refractory chronic migraine: a consensus statement on clinical definition from the European headache federation. J Headache Pain. 2014;15:47.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med. 2007;13:39–44.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ. The vascular theory of migraine - a great story wrecked by the facts. Brain. 2009;132:6–7.
   PubMed Web of Science ®Google Scholar
• Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci. 2011;12:570–584.
   PubMed Web of Science ®Google Scholar
• Amara SG, Jonas V, Rosenfeld MG, et al. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature. 1982;298:240–244.
   PubMed Web of Science ®Google Scholar
• Eftekhari S, Salvatore CA, Johansson S, et al. Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the bloodbrain barrier. Brain Res. 2015;1600:93–109.
   PubMed Web of Science ®Google Scholar
• Recober A, Russo AF. Calcitonin gene-related peptide: an update on the biology. Curr Opin Neurol. 2009;22:241–246.
   PubMed Web of Science ®Google Scholar
• Benarroch EE. CGRP: sensory neuropeptide with multiple neurologic implications. Neurology. 2011;77:281–287.
   PubMed Web of Science ®Google Scholar
• Moore EL, Salvatore CA. Targeting a family B GPCR/RAMP receptor complex: CGRP receptor antagonists and migraine. Br J Pharmacol. 2012;166:66–78.
   PubMed Web of Science ®Google Scholar
• Eftekhari S, Salvatore CA, Calamari A, et al. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience. 2010;169:683–696.
   PubMed Web of Science ®Google Scholar
• Unger JW, Lange W. Immunohistochemical mapping of neurophysins and calcitonin gene-related peptide in the human brainstem and cervical spinal cord. J Chem Neuroanat. 1991;4:299–309.
   PubMed Web of Science ®Google Scholar
• Brain SD, Grant AD. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev. 2004;84:903–934.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Ekman R, Jansen I, et al. Calcitonin gene-related peptide and cerebral blood vessels: distribution and vasomotor effects. J Cereb Blood Flow Metab. 1987;7:720–728.
   PubMed Web of Science ®Google Scholar
• Brain SD, Hughes SR, Cambridge H, et al. The contribution of calcitonin gene-related peptide (CGRP) to neurogenic vasodilator responses. Agents Actions. 1993;38:C19–C21.
   Google Scholar
• Asghar MS, Hansen AE, Amin FM, et al. Evidence for a vascular factor in migraine. Ann Neurol. 2011;69:635–645.
   PubMed Web of Science ®Google Scholar
• Raddant AC, Russo AF. Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation. Expert Rev Mol Med. 2011;13:e36.
   PubMed Web of Science ®Google Scholar
• Bernstein C, Burstein R. Sensitization of the trigeminovascular pathway: perspective and implications to migraine pathophysiology. J Clin Neurol. 2012;8:89–99.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Winborn CS, Marquez de Prado B, et al. Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J Neurosci. 2007;27:2693–2703.
   PubMed Web of Science ®Google Scholar
• Theoharides TC, Donelan J, Kandere-Grzybowska K, et al. The role of mast cells in migraine pathophysiology. Brain Res Rev. 2005;49:65–76.
   PubMedGoogle Scholar
• Capuano A, De Corato A, Lisi L, et al. Proinflammatory-activated trigeminal satellite cells promote neuronal sensitization: relevance for migraine pathology. Mol Pain. 2009;5:43.
   PubMed Web of Science ®Google Scholar
• De Corato A, Lisi L, Capuano A, et al. Trigeminal satellite cells express functional calcitonin gene-related peptide receptors, whose activation enhances interleukin-1β pro- inflammatory effects. J Neuroimmunol. 2011;237:39–46.
   PubMed Web of Science ®Google Scholar
• Marvizón JCG, Pérez OA, Song B, et al. Calcitonin receptor-like receptor and receptor activity modifying protein 1 in the rat dorsal horn: localization in glutamatergic presynaptic terminals containing opioids and adrenergic α2C receptors. Neuroscience. 2007;148:250–265.
   PubMed Web of Science ®Google Scholar
• Fischer MJM. Calcitonin gene-related peptide receptor antagonists for migraine. Expert Opin Investig Drugs. 2010;19:815–823.
   PubMed Web of Science ®Google Scholar
• Sink KS, Walker DL, Yang Y, et al. Calcitonin gene-related peptide in the bed nucleus of the stria terminalis produces an anxiety-like pattern of behavior and increases neural activation in anxiety-related structures. J Neurosci. 2011;31:1802–1810.
   PubMed Web of Science ®Google Scholar
• Neugebauer V, Li W, Bird GC, et al. The amygdala and persistent pain. Neuroscientist. 2004;10:221–234.
   PubMed Web of Science ®Google Scholar
• Eikermann-Haerter K, Negro A, Ayata C. Spreading depression and the clinical correlates of migraine. Rev Neurosci. 2013;24:353–363.
   PubMed Web of Science ®Google Scholar
• Zhang X, Levy D, Noseda R, et al. Activation of meningeal nociceptors by cortical spreading depression: implications for migraine with aura. J Neurosci. 2010;30:8807–8814.
   PubMed Web of Science ®Google Scholar
• Zhang X, Levy D, Kainz V, et al. Activation of central trigeminovascular neurons by cortical spreading depression. Ann Neurol. 2011;69:855–865.
   PubMed Web of Science ®Google Scholar
• Levy D. Migraine pain and nociceptor activation–where do we stand? Headache. 2010;50:909–916.
   PubMed Web of Science ®Google Scholar
• Reuter U, Weber JR, Gold L, et al. Perivascular nerves contribute to cortical spreading depression-associated hyperemia in rats. Am J Physiol. 1998;274:H1979–H1987.
   PubMedGoogle Scholar
• Wahl M, Schilling L, Parsons AA, et al. Involvement of calcitonin gene-related peptide (CGRP) and nitric oxide (NO) in the pial artery dilatation elicited by cortical spreading depression. Brain Res. 1994;637:204–210.
   PubMed Web of Science ®Google Scholar
• Recober A, Kuburas A, Zhang Z, et al. Role of calcitonin gene-related peptide in light-aversive behavior: implications for migraine. J Neurosci. 2009;29:8798–8804.
   PubMed Web of Science ®Google Scholar
• Recober A, Kaiser EA, Kuburas A, et al. Induction of multiple photophobic behaviors in a transgenic mouse sensitized to CGRP. Neuropharmacology. 2010;58:156–165.
   PubMed Web of Science ®Google Scholar
• Kaiser EA, Kuburas A, Recober A, et al. Modulation of CGRP-induced light aversion in wild-type mice by a 5-HT1B/D agonist. J Neurosci. 2012;32:15439–15449.
   PubMed Web of Science ®Google Scholar
• Mulderry PK, Ghatei MA, Spokes RA, et al. Differential expression of alpha-CGRP and beta-CGRP by primary sensory neurons and enteric autonomic neurons of the rat. Neuroscience. 1988;25:195–205.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988;23:193–196.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28:183–187.
   PubMed Web of Science ®Google Scholar
• Cady RK, Vause CV, Ho TW, et al. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache. 2009;49:1258–1266.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33:48–56.
   PubMed Web of Science ®Google Scholar
• Ashina M, Bendtsen L, Jensen R, et al. Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks. Pain. 2000;86:133–138.
   PubMed Web of Science ®Google Scholar
• Cernuda-Morollón E, Larrosa D, Ramón C, et al. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013;81:1191–1196.
   PubMed Web of Science ®Google Scholar
• Hansen JM, Hauge AW, Olesen J, et al. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010;30:1179–1186.
   PubMed Web of Science ®Google Scholar
• Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350:1104–1110.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Linde M. New drugs in migraine treatment and prophylaxis: telcagepant and topiramate. Lancet. 2010;376:645–655.
   PubMed Web of Science ®Google Scholar
• Mathew NT. Pathophysiology of chronic migraine and mode of action of preventive medications. Headache. 2011;51:84–92.
   PubMed Web of Science ®Google Scholar
• Aoki KR. Review of a proposed mechanisms for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 2005;26:785–793.
   PubMed Web of Science ®Google Scholar
• Matak I, Lacković Z. Botulinum toxin A, brain and pain. Prog Neurobiol. 2014;119–120:39–59.
   PubMed Web of Science ®Google Scholar
• Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache. 2004;44:35–42.
   PubMed Web of Science ®Google Scholar
• Gazerani P, Au S, Dong X, et al. Botulinum neurotoxin type A (BoNTA) decreases the mechanical sensitivity of nociceptors and inhibits neurogenic vasodilation in a craniofacial muscle targeted for migraine prophylaxis. Pain. 2010;151:606–616.
   PubMed Web of Science ®Google Scholar
• Cernuda-Morollón E, Ramón C, Martínez-Camblor P, et al. OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine. Pain. 2015;156:820–824.
   PubMed Web of Science ®Google Scholar
• Khalil M, Zafar HW, Quarshie V, et al. Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK. J Headache Pain. 2014;15:54.
   PubMed Web of Science ®Google Scholar
• Grazzi L, Usai S. Onabotulinum toxin A (Botox) for chronic migraine treatment: an Italian experience. Neurol Sci. 2015;36(Suppl 1):S33–S35.
   PubMed Web of Science ®Google Scholar
• Pedraza MI, de la Cruz C, Ruiz M, et al. OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm. Springerplus. 2015;13:176.
   Web of Science ®Google Scholar
• Cernuda-Morollón E, Ramón C, Larrosa D, et al. Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: what happens after one year? Cephalalgia. 2015;35:864–868.
   PubMed Web of Science ®Google Scholar
• Negro A, Curto M, Lionetto L, et al. OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study. Springerplus. 2015;4:826.
   PubMed Web of Science ®Google Scholar
• Negro A, Curto M, Lionetto L, et al. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. J Headache Pain. 2015;17:1.
   PubMed Web of Science ®Google Scholar
• Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008;372:2115–2123.
   PubMed Web of Science ®Google Scholar
• Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008;70:1304–1312.
   PubMed Web of Science ®Google Scholar
• Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011;31:712–2.
   PubMed Web of Science ®Google Scholar
• Diener HC, Barbanti P, Dahlof C, et al. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia. 2011;31:573–584.
   PubMed Web of Science ®Google Scholar
• Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014;34:114–125.
   PubMed Web of Science ®Google Scholar
• Gupta S, Mehrotra S, Avezaat CJJ, et al. Characterization of CGRP receptors in the human isolated middle meningeal artery. Life Sci. 2006;79:265–271.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Chan KY, Eftekhari S, et al. Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries. Cephalalgia. 2010;30:1233–1240.
   PubMed Web of Science ®Google Scholar
• Chan KY, Edvinsson L, Eftekhari S, et al. Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries. J Pharmacol Exp Ther. 2010;334:746–752.
   PubMed Web of Science ®Google Scholar
• Cui XP, Ye JX, Lin H, et al. Efficacy, safety, and tolerability of telcagepant in the treatment of acute migraine: a meta-analysis. Pain Pract. 2015;15:124–131.
   PubMed Web of Science ®Google Scholar
• Miranda LP, Shi L, Holder JR, et al. Peptide antagonists of the calcitonin gene-related peptide (CGRP) receptor with improved pharmacokinetics and pharmacodynamics. Biopolymers. 2013;100:422–430.
   PubMed Web of Science ®Google Scholar
• Joshi P, Anderson C, Binch H, et al. Identification of potent CNS-penetrant thiazolidinones as novel CGRP receptor antagonists. Bioorg Med Chem Lett. 2014;24:845–849.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Goadsby PJ, Silberstein SD, et al. ALD403 study investigators. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014;13:1100–1107.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Goadsby PJ, Spierings EL, et al. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2014;13:885–892.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Dodick DW, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14:1081–1090.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Edvinsson L, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14:1091–1100.
   PubMed Web of Science ®Google Scholar
• Sun H, Dodick DW, Silberstein S, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15:382–390.
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Birbeck GL, Jensen RH, et al. Headache disorders are third cause of disability worldwide. J Headache Pain. 2015;16:58.
   PubMed Web of Science ®Google Scholar
• Negro A, Lionetto L, Simmaco M, et al. CGRP receptor antagonists: an expanding drug class for acute migraine? Expert Opin Investig Drugs. 2012;21:807–818.
   PubMed Web of Science ®Google Scholar
• Giamberardino MA, Affaitati G, Curto M, et al. Emerging treatments for the primary headache disorders. Intern Emerg Med. 2016. doi:10.1007/s11739-016-1489-4.
   PubMedGoogle Scholar
• Wrobel Goldberg S, Silberstein SD. Targeting CGRP: a New Era for migraine treatment. CNS Drugs. 2015;29:443–452.
   PubMed Web of Science ®Google Scholar
• Zeller J, Poulsen KT, Sutton JE, et al. CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat. Br J Pharmacol. 2008;155:1093–1103.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Walter S, Bronson M, et al. Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP. Cephalalgia. 2014;34:968–976.
   PubMed Web of Science ®Google Scholar
• Walter S, Alibhoy A, Escandon R, et al. Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide. mAbs. 2014;6:871–878.
   PubMed Web of Science ®Google Scholar
• Descotes J. Immunotoxicity of monoclonal antibodies. mAbs. 2009;1:104–111.
   PubMed Web of Science ®Google Scholar
• Pascual J. CGRP antibodies: the Holy Grail for migraine prevention? Lancet Neurol. 2015;14:1066–1067.
   PubMed Web of Science ®Google Scholar
• Ramos ML, Pascual J. AMG 334 CGRP antibody for migraine: time to celebrate? Lancet Neurol. 2016;15:347–349.
   PubMed Web of Science ®Google Scholar
• Cernuda-Morollón E, Martínez-Camblor P, Ramón C, et al. CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine. Headache. 2014;54:987–995.
   PubMed Web of Science ®Google Scholar
• Silberstein S, Lenz R, Xu C. Therapeutic monoclonal antibodies: what headache specialists need to know. Headache. 2015;55:1171–1182.
   PubMed Web of Science ®Google Scholar
• Berger A, Bloudek LM, Varon SF, et al. Adherence with migraine prophylaxis in clinical practice. Pain Pract. 2012;12:541–549.
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Olesen J. Possible site of action of CGRP antagonists in migraine. Cephalalgia. 2011;31:748–750.
   PubMed Web of Science ®Google Scholar
• Edvinsson L. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Pharmacol. 2015;80:193–199.
   PubMed Web of Science ®Google Scholar
• Edvinsson L. CGRP blockers in migraine therapy: where do they act? Br J Pharmacol. 2008;155:967–969.
   PubMed Web of Science ®Google Scholar
• Lynch JJ Jr, Regan CP, Edvinsson L, et al. Comparison of the vasoconstrictor effects of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) and zolmitriptan in human isolated coronary arteries. J Cardiovasc Pharmacol. 2010;55:518–521.
   PubMed Web of Science ®Google Scholar
• Smillie SJ, King R, Kodji X, et al. An ongoing role of α-calcitonin gene- related peptide as part of a protective network against hypertension, vascular hypertrophy, and oxidative stress. Hypertension. 2014;63:1056–1062.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide Changes and Effects of Acute Attacks Therapies. Brain. 1994;117(Pt 3):427–434.
   PubMed Web of Science ®Google Scholar